Literature DB >> 8282333

Angiotensin converting enzyme inhibition prevents the increase in aortic collagen in rats.

P Albaladejo1, H Bouaziz, M Duriez, P Gohlke, B I Levy, M E Safar, A Benetos.   

Abstract

Four groups of 4-week-old spontaneously hypertensive rats were treated during 4 months with the angiotensin converting enzyme inhibitor quinapril at 1 mg/kg per day (Q1) or 10 mg/kg per day (Q10), hydralazine at 15 mg/kg per day (H), or placebo (P). In the first set of experiments, blood pressure was measured in conscious rats, and plasma and aortic angiotensin converting enzyme activities were evaluated. In the second set of experiments, histomorphometric parameters of the thoracic aorta were evaluated. Mean blood pressure was lower in the Q10 and H groups (136 +/- 16 and 149 +/- 11 mm Hg) compared with the P group (190 +/- 23 mm Hg) (P < .01). The Q1 group showed mean blood pressure values (171 +/- 15 mm Hg) lower than the P group (P < .05) but significantly higher than the Q10 and H groups (P < .01 and P < .05, respectively). Aortic medial cross-sectional area was significantly lower in the H and Q10 groups (455 +/- 61 and 487 +/- 57 x 10(3) microns 2) than in the P group (636 +/- 72 x 10(3) microns 2) (P < .001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8282333     DOI: 10.1161/01.hyp.23.1.74

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  15 in total

Review 1.  Pharmacological modulation of arterial stiffness.

Authors:  Pierre Boutouyrie; Patrick Lacolley; Marie Briet; Véronique Regnault; Alice Stanton; Stéphane Laurent; Azra Mahmud
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

Review 2.  Genetic determinants of arterial stiffness.

Authors:  Jeongok G Logan; Mary B Engler; Hyungsuk Kim
Journal:  J Cardiovasc Transl Res       Date:  2014-12-04       Impact factor: 4.132

3.  Distribution of the activity of the angiotensin-converting enzyme in the rat aorta and changes in the activity with aging and by the action of L-NAME.

Authors:  Antonina F Korystova; Maksim O Emel'yanov; Ludmila N Kublik; Maria Kh Levitman; Vera V Shaposhnikova; Yuri A Kim; Yuri N Korystov
Journal:  Age (Dordr)       Date:  2011-07-01

Review 4.  Arterial stiffness as a risk factor for clinical hypertension.

Authors:  Michel E Safar
Journal:  Nat Rev Cardiol       Date:  2017-10-12       Impact factor: 32.419

5.  Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure.

Authors:  B I Levy; J Benessiano; D Henrion; L Caputo; C Heymes; M Duriez; P Poitevin; J L Samuel
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

6.  Angiotensin II induces a region-specific hyperplasia of the ascending aorta through regulation of inhibitor of differentiation 3.

Authors:  A Phillip Owens; Venkateswaran Subramanian; Jessica J Moorleghen; Zhenheng Guo; Coleen A McNamara; Lisa A Cassis; Alan Daugherty
Journal:  Circ Res       Date:  2009-12-17       Impact factor: 17.367

Review 7.  Vascular Smooth Muscle Remodeling in Conductive and Resistance Arteries in Hypertension.

Authors:  Isola A M Brown; Lukas Diederich; Miranda E Good; Leon J DeLalio; Sara A Murphy; Miriam M Cortese-Krott; Jennifer L Hall; Thu H Le; Brant E Isakson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

Review 8.  Extracellular matrix fibrotic markers in heart failure.

Authors:  Faiez Zannad; Patrick Rossignol; Wafae Iraqi
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

9.  Favorable cardiac and aortic remodeling in olmesartan-treated spontaneously hypertensive rats.

Authors:  Caroline Fernandes-Santos; Leonardo de Souza Mendonça; Carlos Alberto Mandarim-de-Lacerda
Journal:  Heart Vessels       Date:  2009-05-24       Impact factor: 2.037

Review 10.  Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.

Authors:  G L Plosker; E M Sorkin
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.